Johnson & Johnson and AbbVie’s Imbruvica has enjoyed a nice run in previously untreated chronic lymphocytic leukemia over the last few years. But major competition is here in the form of AstraZeneca’s Calquence. Thursday, the FDA—along with regulators in Canada
read moreJohnson & Johnson faces lawsuits over opioids, talc, medical devices—and now, thousands more featuring the antipsychotic drug Risperdal. Pennsylvania’s Supreme Court on Wednesday revived a raft of previously tossed-out claims alleging the drug caused males to develop breasts. More: J&J
read moreFrom Roche and Novartis’ aging Xolair to Sanofi and Regeneron’s newcomer Dupixent, along with meds from respiratory nemeses AstraZeneca and GlaxoSmithKline, several biologics are vying for a bigger share of the asthma market. Which one of them do doctors prefer?
read moreMore: Manufacturing News of Note—Dr. Reddy's to have CDMOs produce some of its drugs in China Source: fierce
read moreAmgen has its $13.4 billion purchase of Celgene’s psoriasis blockbuster Otezla in the bag, but will the buy pay off to the extent the company is predicting? Analysts are cautiously optimistic. More: Amgen juices up sales outlook amid high hopes
read moreNew NHS statistics show an increase in uptake for the first time in five years. More: Smear test numbers rise 7.7% Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals